FDA

Summary: Doctors are preparing to administer lecanemab, a promising new Alzheimer’s disease treatment nearing FDA approval. This therapy, marketed as Leqembi, slows cognitive decline by extracting the amyloid protein from the brain, thereby reducing the accumulation of tau protein. Treatment, especially for patients with mild cognitive impairment or mild dementia in Alzheimer’s disease, involves a … Read more